Skip to main content

Table 3 Case characteristics and treatment costs by third-line interventions

From: Health economic analysis of third-line interventions in diffuse large B-cell lymphomas in Germany: applying the efficiency frontier

 

BSC

alloSCT

CAR T

tisa-cel

axi-cel

Patients no. (%)

11 (17.74)

14 (22.58)

20 (32.26)

17 (27.42)

Sex no. (%)

    

Female

3 (4.84)

7 (11.29)

12 (19.35)

6 (9.68)

Male

8 (12.90)

7 (11.29)

8 (12.90)

11 (17.74)

Agea

63 [32–83]

49 [20–66]

60 [23–82]

62 [24–79]

Casemix index†

6.97 [0.98–31.25]

14.38 [10.56–16.98]

1.70 [1.18–47.71]

3.17 [1.59–29.52]

Length of stay in daysa

52 [13–130]

38 [23–51]

21 [12–110]

28 [19–111]

Number of side diagnosesa

18 [5–47]

19 [13–41]

11.5 [2–51]

21 [10–43]

Treatment costsa

€ 26,918 [€ 0.00–€ 66,468]

€ 73,829 [€ 61,337–€ 133,280]

€ 310,496 [€ 294,113–€ 557,423]

€ 340,458 [€ 316,272–€ 502,096]

  1. aMedian values [range]